3 FEB. 2023, 4:45 P.M. BY KATHERINE KORNEI MRI scans of a man whose brain was infected with the amoeba Balamuthia mandrillaris show a dramatic difference in inflammation (white) before and after (right) treatment with an experimental drug.N. SPOTTISWOODE ET AL., EMERG. INFECT. DIS. (1) 197-201 (2023) In the summer of 2021, a 54-year-old man was brought to...
3 FEB 2023, 4:45 PM BY KATHERINE KORNEI MRI scans of a man whose brain was infected with the amoeba Balamuthia mandrillaris show a dramatic difference in inflammation (white) before and after (right) treatment with an experimental drug.N. SPOTTISWOODE ET AL., EMERG. INFECT. DIS. (1) 197-201 (2023) In the summer of 2021, a 54-year-old man was brought to...
by University of Edinburgh Credit: Unsplash/CC0 Public Domain A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND)—also known as amyotrophic lateral sclerosis (ALS)—according to a new study. MND is a group of rare diseases that destroy nerve cells known as motor...
by Quinn Eastman, Emory University Figure 1: Trial profile. SOC=standard of care. *Included in the intent-to-treat population. †Includes all randomized participants who received ≥1 dose of study drug and who did not discontinue the study for the reason of ‘lost to follow-up’ at the first post-baseline visit. ‡159 deaths total reported by day 28. There were...
by Alice McCarthy, Harvard Medical School Researchers have found that an existing drug, apilimod, prevented infection of human cells with the SARS-CoV-2 virus. Credit: Tomas Kirchhausen New lab-based studies show that two existing drugs, including one developed by a researcher at Harvard Medical School and Boston Children’s Hospital, inhibit SARS-CoV-2—the virus that causes COVID-19—from infecting...
by Kayla Wiles, Purdue University Doug Brubaker, a Purdue assistant professor of biomedical engineering, uses computational and experimental approaches to study host-microbiome interactions in cancers and inflammatory diseases. Credit: Purdue University /John Underwood About 50% of people who take the drug infliximab for inflammatory bowel diseases, such as Crohn’s disease, end up becoming resistant or...
Prediabetes progresses into diabetes in 5-10 per cent of patients within ten years, say researchers. A weight loss drug has reduced the risk of type 2 diabetes by 80 per cent compared to placebo. The drug, which increases the amount of appetite-supressing hormones produced by the gut, was tested on overweight people with ‘prediabetes’. This...
